Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia
© 2020 Bhavana Bhatnagar..
AIM: There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase.
MATERIALS & METHODS: Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed.
RESULTS: 18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender.
CONCLUSION: These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
International journal of hematologic oncology - 9(2020), 3 vom: 04. Sept., Seite IJH28 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Underwood, Brynne [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute lymphoblastic leukemia |
|---|
| Anmerkungen: |
Date Revised 17.04.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2217/ijh-2020-0009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315846178 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315846178 | ||
| 003 | DE-627 | ||
| 005 | 20231225155809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/ijh-2020-0009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315846178 | ||
| 035 | |a (NLM)33014332 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Underwood, Brynne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 Bhavana Bhatnagar. | ||
| 520 | |a AIM: There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase | ||
| 520 | |a MATERIALS & METHODS: Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed | ||
| 520 | |a RESULTS: 18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender | ||
| 520 | |a CONCLUSION: These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute lymphoblastic leukemia | |
| 650 | 4 | |a adolescent young adult | |
| 650 | 4 | |a peg-asparaginase | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a venous thromboembolism | |
| 700 | 1 | |a Zhao, Qiuhong |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Alison R |e verfasserin |4 aut | |
| 700 | 1 | |a Mims, Alice S |e verfasserin |4 aut | |
| 700 | 1 | |a Vasu, Sumithira |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Meixiao |e verfasserin |4 aut | |
| 700 | 1 | |a Z Haque, Tamanna |e verfasserin |4 aut | |
| 700 | 1 | |a Blaser, Bradley W |e verfasserin |4 aut | |
| 700 | 1 | |a Grieselhuber, Nicole R |e verfasserin |4 aut | |
| 700 | 1 | |a Wall, Sarah A |e verfasserin |4 aut | |
| 700 | 1 | |a Behbehani, Gregory K |e verfasserin |4 aut | |
| 700 | 1 | |a Blachly, James S |e verfasserin |4 aut | |
| 700 | 1 | |a Larkin, Karilyn |e verfasserin |4 aut | |
| 700 | 1 | |a Byrd, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Garzon, Ramiro |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tzu-Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatnagar, Bhavana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of hematologic oncology |d 2012 |g 9(2020), 3 vom: 04. Sept., Seite IJH28 |w (DE-627)NLM225668882 |x 2045-1393 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:3 |g day:04 |g month:09 |g pages:IJH28 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/ijh-2020-0009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 3 |b 04 |c 09 |h IJH28 | ||